Viridian Therapeutics Inc (VRDN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.51B
Last updated: Nov 17, 2026 at 11:05 AM ET
Viridian Therapeutics Inc (VRDN) Stock Forecast
Analysts expect Viridian Therapeutics (VRDN) to earn -$3.51 per share in the fiscal year ending Dec 31, 2026, on revenue of $74.76M. Of 17 analysts, 17 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 1.82, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 17.6% |
| Buy | 14 | 82.4% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 318.3%.
- Fiscal year ending Dec 31, 2026
- -$3.51
- EPS consensus, revenue $74.76M
- Fiscal year ending Dec 31, 2027
- -$2.13
- EPS consensus, revenue $312.69M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.51 | -$3.98 to -$2.81 | 13 | $74.76M | $55.91M to $97.48M | 13 |
| Dec 31, 2027 | -$2.13 | -$3.94 to -$1.36 | 13 | $312.69M | $134.00M to $476.91M | 14 |
Quarterly Estimates
The EPS consensus falls from -$0.72 for the quarter ending Dec 31, 2026 to -$0.75 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.72 | -$0.83 to -$0.61 | 16 | $50.04M | $30.29M to $74.87M | 16 |
| Mar 31, 2027 | -$0.75 | -$0.95 to -$0.53 | 4 | $67.96M | $53.00M to $82.81M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 13 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 1 |
| Fiscal year ending Dec 31, 2027 | 7 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.51 | -$3.92 | -$3.93 | -$3.95 | -$3.95 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.13 | -$2.71 | -$2.75 | -$2.77 | -$2.77 | N/A |
| Quarter ending Mar 31, 2027 | -$0.75 | -$0.88 | -$0.89 | -$0.89 | -$0.89 | N/A |
Frequently Asked Questions About VRDN
What is the VRDN stock forecast?
Consensus analyst estimates put Viridian Therapeutics's EPS at -$3.51 for the fiscal year ending Dec 31, 2026, on revenue of $74.76M. The consensus rating from 17 analysts is Buy.
How do analysts rate VRDN stock?
Of 17 analysts covering Viridian Therapeutics, 3 rate it Strong Buy, 14 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VRDN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.51, with estimates from -$3.98 to -$2.81 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.13, with estimates from -$3.94 to -$1.36 from 13 analysts.
What revenue do analysts expect from Viridian Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $74.76M, with estimates from $55.91M to $97.48M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $312.69M, with estimates from $134.00M to $476.91M.
How many analysts cover VRDN?
17 analysts rate Viridian Therapeutics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VRDN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors